Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses
Menglin Wang,Benoit Rousseau,Kunyu Qiu,Guannan Huang,Yu Zhang,Hang Su,Christine Le Bihan-Benjamin,Ines Khati,Oliver Artz,Michael B. Foote,Yung-Yi Cheng,Kuo-Hsiung Lee,Michael Z. Miao,Yue Sun,Philippe-Jean Bousquet,Marc Hilmi,Elise Dumas,Anne-Sophie Hamy,Fabien Reyal,Lin Lin,Paul M. Armistead,Wantong Song,Ava Vargason,Janelle C. Arthur,Yun Liu,Jianfeng Guo,Xuefei Zhou,Juliane Nguyen,Yongqun He,Jenny P.-Y. Ting,Aaron C. Anselmo,Leaf Huang
DOI: https://doi.org/10.1038/s41587-023-01957-8
IF: 46.9
2023-09-26
Nature Biotechnology
Abstract:Increasing evidence implicates the tumor microbiota as a factor that can influence cancer progression. In patients with colorectal cancer (CRC), we found that pre-resection antibiotics targeting anaerobic bacteria substantially improved disease-free survival by 25.5%. For mouse studies, we designed an antibiotic silver-tinidazole complex encapsulated in liposomes (LipoAgTNZ) to eliminate tumor-associated bacteria in the primary tumor and liver metastases without causing gut microbiome dysbiosis. Mouse CRC models colonized by tumor-promoting bacteria ( Fusobacterium nucleatum spp.) or probiotics ( Escherichia coli Nissle spp.) responded to LipoAgTNZ therapy, which enabled more than 70% long-term survival in two F. nucleatum -infected CRC models. The antibiotic treatment generated microbial neoantigens that elicited anti-tumor CD8 + T cells. Heterologous and homologous bacterial epitopes contributed to the immunogenicity, priming T cells to recognize both infected and uninfected tumors. Our strategy targets tumor-associated bacteria to elicit anti-tumoral immunity, paving the way for microbiome–immunotherapy interventions.
biotechnology & applied microbiology